comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 21:34:14 - browse：944

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Coercive sterilizations revealed by STAT prompt outrage

focus

WSS

Report captures long Covid’s disabling effects and policy challenges

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Long Covid research funding gets a major boost from NIH

Medical device trials still don't enroll enough women, study finds

ALS patient reclaims some autonomy thanks to wearable 'robot'

STAT Boddities: What happens to the brain when we get scared?

focus

comprehensive

hotspot

Hollywood unions extend contract negotiations for actors

Artificial intelligence use in health care faces greater scrutiny in 2024

Duchenne breakthrough therapy leaves behind pioneering families

Having children helps parents live longer, especially after age 80

Activists slam private health insurers over coverage restrictions

Study gives hint on South Asians’ higher risk of cardiovascular disease

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Report cites 'urgent' need to recruit more diverse clinical trial participants

Anesthesiologist group: stop taking Ozempic before surgery

Why don't Americans have at

knowledge

Cheap, fast test for Zika and dengue could cost just $1

Report captures long Covid’s disabling effects and policy challenges

Bernie Sanders gets little from pharma CEOs on drug prices

Ebola vaccine can save some who are already sick, per new study

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Latigo launches with $135 million for Vertex

hotspot

focus

explore

leisure time